Realizing the clinical potential of ischemic preconditioning and postconditioning

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 11, 2005, Pages 568-575

  Yellon, Derek M ^a   Hausenloy, Derek J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Ischemic postconditioning; Ischemic preconditioning; Kinases; Mitochondrial permeability transition pore; Reperfusion injury

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; ATORVASTATIN; CYCLOOXYGENASE 2; CYCLOSPORIN A; ERYTHROPOIETIN; FIBRINOLYTIC AGENT; GLUCAGON LIKE PEPTIDE 1; HEAT SHOCK PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICORANDIL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; SANGLIFEHRIN A;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; BLOOD CLOT LYSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; GENE TRANSFER; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; MORTALITY; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; PROGNOSIS; RABBITS; RATS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 27844440474     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0346     Document Type: Review

References (62)

1. Fuster V (1999) Epidemic of cardiovascular disease and stroke: The three main challenges. Presented at the 71st scientific sessions of the American Heart Association. Dallas, Texas. Circulation 99: 1132-1137
2. Braunwald E and Kloner RA (1985) Myocardial reperfusion: A double-edged sword? J Clin Invest 76: 1713-1719
3. Bolli R et al. (2004) Myocardial protection at a crossroads: The need for translation into clinical therapy. Circ Res 95: 125-134
4. Kloner RA and Rezkalla SH (2004) Cardiac protection during acute myocardial infarction: Where do we stand in 2004? J Am Coll Cardiol 44: 276-286
5. Kloner RA et al. (1998) Medical and cellular implications of stunning, hibernation, and preconditioning: An NHLBI workshop. Circulation 97: 1848-1867
6. Murry CE (1986) Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136
7. Zhao ZQ et al. (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H579-H588
8. Yellon DM and Downey JM (2003) Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiol Rev 83: 1113-1151
9. Marber MS et al. (1993) Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88: 1264-1272
10. + channels. Possible mechanism of cardioprotection. Circ Res 81: 1072-1082
11. Vanden Hoek TL et al. (1998) Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. J Biol Chem 273: 18092-18098
12. Hausenloy DJ et al. (2002) Inhibiting mitochondrial permeability transition pore opening: A new paradigm for myocardial preconditioning? Cardiovasc Res 55: 534-543
13. Ikonomidis JS et al. (1994) Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischaemia. Cardiovasc Res 28: 1285-1291
14. Walker DM et al. (1995) Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol 27: 1349-1357
15. Williams DO et al. (1985) Adaptation to the stress of tachycardia in patients with coronary artery disease: Insight into the mechanism of the warm-up phenomenon. Circulation 71: 687-692
16. Rezkalla SH and Kloner RA (2004) Ischemic preconditioning and preinfarction angina in the clinical arena. Nat Clin Pract Cardiovasc Med 1: 96-102
17. Deutsch E et al. (1990) Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation 82: 2044-2051
18. Jenkins DP et al. (1995) Preconditioning the human myocardium: Recent advances and aspirations for the development of a new means of cardioprotection in clinical practice. Cardiovasc Drugs Ther 9: 739-747
19. Moolman JA et al. (1997) Ischaemic preconditioning does not protect hypertrophied myocardium against ischaemia. S Afr Med J 87 (Suppl 3): C151-C156
20. Schulman D et al. (2001) Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 281: H1630-H1636
21. Tsang A et al. (2005) Preconditioning the diabetic heart: The importance of Akt phosphorylation. Diabetes 54: 2360-2364
22. IONA Study group (2002) Effect of nicorandil on coronary events in patients with stable angina: The Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359: 1269-1275
23. Ono H et al. (2004) Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Role of inhibitory effect on reactive oxygen species formation. Am Heart J 148: E15
24. + exchange inhibitors for cardioprotective therapy: Progress, problems and prospects. J Am Coll Cardiol 39: 747-753
25. Bolli R (2003) The role of sodium-hydrogen ion exchange in patients undergoing coronary artery bypass grafting. J Card Surg 18 (Suppl 1): 21-26
26. Quintana M et al. (2004) Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent. Am J Cardiovasc Drugs 4: 159-167
27. 1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol 31: 1142-1149
28. Yellon DM and Baxter GF (1999) Reperfusion injury revisited: Is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 9: 245-249
29. Hausenloy DJ and Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: Targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61: 448-460
30. Heusch G (2004) Postconditioning: Old wine in a new bottle? J Am Coll Cardiol 44: 1111-1112
31. Tsang A (2004) Postconditioning: A form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95: 230-232
32. Okamoto F et al. (1986) Reperfusion conditions: Importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion. J Thorac Cardiovasc Surg 92: 613-620
33. Sato H et al. (1997) Gradual reperfusion reduces infarct size and endothelial injury but augments neutrophil accumulation. Ann Thorac Surg 64: 1099-1107
34. Yang XM et al. (2004) Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44: 1103-1110
35. Argaud L et al. (2005) Postconditioning inhibits mitochondrial permeability transition. Circulation 111: 194-197
36. Hausenloy DJ et al. (2005) The reperfusion injury salvage kinase pathway: A common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15: 69-75
37. Downey JM and Cohen MV (2005) We think we see a pattern emerging here. Circulation 111: 120-121
38. Hausenloy DJ et al. (2005) Ischemic preconditioning protects by activating pro-survival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288: H971-H976
39. Griffiths EJ and Halestrap AP (1995) Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 307 (Pt 1): 93-98
40. Hausenloy DJ and Yellon DM (2003) The mitochondrial permeability transition pore: Its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35: 339-341
41. Jonassen AK (2001) Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89: 1191-1198
42. Bell RM and Yellon DM (2003) Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41: 508-515
43. Bullard AJ et al. (2005) Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol [doi: 10.1007/ s00395-005-0537-4]
44. Bose AK et al. (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151
45. Mensah K et al. (2005) Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45: 1287-1291
46. Hausenloy DJ et al. (2003) Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60: 617-625
47. Halkos ME et al. (2004) Myocardial protection with postconditioning is not enhanced by ischemic preconditioning. Ann Thorac Surg 78: 961-969
48. Fath-Ordoubadi F and Beatt KJ (1997) Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials. Circulation 96: 1152-1156
49. Mehta SR et al. (2005) Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 293: 437-446
50. Apstein CS and Opie LH (2005) A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J 26: 956-959
51. Ehrenreich H et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495-505
52. Nikolaidis LA et al. (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962-965
53. Kin H et al. (2004) Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 62: 74-85
54. Galagudza M et al. (2004) Ischemic postconditioning: Brief ischemia during reperfusion converts persistent ventricular fibrillation into regular rhythm. Eur J Cardiothorac Surg 25: 1006-1010
55. Sun K et al. (2004) Role of mitochondria in cell apoptosis during hepatic ischemia-reperfusion injury and protective effect of ischemic postconditioning. World J Gastroenterol 10: 1934-1938
56. Yang XM et al. (2005) Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 100: 57-63
57. Chiari PC et al. (2005) Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: Evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology 102: 102-109
58. Serviddio G et al. (2005) Brief hypoxia before normoxic reperfusion (postconditioning) protects the heart against ischemia-reperfusion injury by preventing mitochondria peroxyde production and glutathione depletion. FASEB J 19: 354-361
59. 2+ overload. Am J Physiol Heart Circ Physiol 288: H1900-H1908
60. Darling CE et al. (2005) 'Postconditioning' via stuttering reperfusion limits myocardial infarct size in rabbit hearts: Role of ERK 1/2. Am J Physiol Heart Circ Physiol [doi:10.1152/ajpheart.00055.2005]
61. Kin H et al. (2005) Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 67: 124-133
62. Kerendi F et al. (2005) Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol [doi: 10.1007/s00395-005-0539-2]